Printer Friendly

Browse Alectinib topic

Articles

1-56 out of 56 article(s)
Title Author Type Date Words
She Never Smoked -- And Got Lung Cancer in Her 40s. Dennis Thompson, HealthDay Reporter Dec 17, 2019 1324
New Zealand : More cancer medicines for more people. Dec 5, 2019 306
More cancer medicines for more people. Dec 5, 2019 295
More progress on cancer medicines. Nov 4, 2019 324
Seattle Genetics (NASDAQ: SGEN). Oct 30, 2019 1843
Pfizer Inc. (NYSE: PFE). Oct 28, 2019 4348
Pfizer UK. Oct 22, 2019 4379
Pfizer Inc (NYSE: PFE). Oct 21, 2019 4348
Seattle Genetics (NASDAQ: SGEN). Oct 17, 2019 1994
Pfizer UK. Oct 15, 2019 4379
Pfizer Inc (NYSE: PFE). Oct 14, 2019 4271
Seattle Genetics (NASDAQ: SGEN). Oct 9, 2019 1805
Pfizer Inc (NYSE: PFE). Oct 7, 2019 4271
More cancer drugs confirmed - even more on horizon. Oct 7, 2019 310
Seattle Genetics (NASDAQ: SGEN). Oct 2, 2019 1843
Pfizer Inc (NYSE: PFE). Oct 1, 2019 4271
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa. Clinical report Sep 30, 2019 1352
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa. Clinical report Sep 30, 2019 1352
Seattle Genetics (NASDAQ: SGEN). Sep 25, 2019 1844
Pfizer UK. Sep 24, 2019 4379
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress. Sep 23, 2019 1237
Seattle Genetics (NASDAQ: SGEN). Sep 19, 2019 1806
2019/443568 Supply Of Exclusive Medicines: Alectinib 150 Mg; Atezolizumab 1200 Mg; Diazepam 10 Mg; Erlotinib 150 Mg, For All Centers Attached To The Health Logistics Platform Of Seville. Sep 14, 2019 109
Procurement Of Tab Alectinib And Tab Olaparib For Echs Clientels. Sep 14, 2019 155
Eli Lilly and Company UK (NYSE: LLY) - Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer -- 9/9/2019. Financial report Sep 11, 2019 806
What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies. Bernicker, Eric H. Sep 1, 2019 3752
Seattle Genetics (NASDAQ: SGEN). Aug 29, 2019 1805
Supply Of The Medicines Atezolizumab (tecentriq), Alectinib (alecensa), Obinutuzumab (gazyvaro) And Pertuzumab (perjeta) For The Pharmacy Service Of The San Pedro De Logroo Hospital, Riojan Health Se. Aug 26, 2019 127
Supply Of Antitumor Medicinal Products For The Treatment Of Solid Tumors For The Needs Of Salo - Haskovo Ltd. At 5 Nomenclature Units, Paid By The Nhif (bulgaria-haskovo: Pharmaceutical Products). Aug 26, 2019 241
Supply Of Exclusive Medicines: Alectinib, Pirfenidone, Obinutuzumab, Dornase Alfa, Rituximab, Atezolizumab, Trastuzumab, Trastuzumab Emtansin. Aug 21, 2019 114
Seattle Genetics (NASDAQ: SGEN). Aug 20, 2019 1806
Seattle Genetics (NASDAQ: SGEN). Aug 13, 2019 1806
Seattle Genetics (NASDAQ: SGEN). Jul 31, 2019 1808
Seattle Genetics (NASDAQ: SGEN). Jul 25, 2019 1844
Seattle Genetics (NASDAQ: SGEN). Jul 17, 2019 1844
Purchase Of Specific Medicines. Jul 2, 2019 539
Brain Metastasis Mimicking Brain Abscess in ALK-Positive Non-Small-Cell Lung Cancer. Sakatani, Toshio; Kage, Hidenori; Takayanagi, Shunsaku; Watanabe, Kaoru; Hiraishi, Yoshihisa; Shinoz Jul 1, 2019 1449
Chugai Pharmaceutical Co., Ltd - Chugai Files for Additional Indication of ALK Inhibitor ALECENSA for Recurrent or Refractory ALK Fusion Gene-Positive Anaplastic Large Cell Lymphoma (ALCL) -- 3/6/2019. Jun 11, 2019 597
Seattle Genetics Appoints Taylor as Chief Commercial Officer. May 24, 2019 383
United States : European Commission Approves Lorviqua (Lorlatinib) for Certain Adult Patients With Previously-treated Alk-positive Advanced Non-small Cell Lung Cancer. May 11, 2019 567
The European Commission grants conditional marketing authorisation for Pfizer's LORVIQUA. May 10, 2019 196
The European Commission grants conditional marketing authorisation for Pfizer's LORVIQUA. May 10, 2019 192
European Commission Approves Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer. May 10, 2019 450
Pfizer says EC grants conditional marketing authorization for LORVIQUA. May 7, 2019 201
Supply Of Antitumour Medicinal Products For The Treatment Of Solid Tumors For The Needs Of Shalo - Haskovo Ltd. For 5 Nomenclature Units Paid By Nhif. Apr 3, 2019 326
Terminally ill mum who hid cancer shrinks tumour 75% after alternative care; Kate Malvenan was given between six and 24 months to live last year when she was diagnosed with lung cancer - but treatment in Mexico has given her new hope. Mar 24, 2019 1109
Conclusion Of Non-exclusive Discount Agreements According To 130a Abs. 8 Sgb V To Those In Ii.2.4. Mentioned Active Substances With Completion Option In The Context Of The So-called Open-house Method. Mar 8, 2019 371
European Medicines Agency's committee recommends Pfizer's lung cancer drug. Mar 5, 2019 188
European Medicines Agency's committee recommends Pfizer's lung cancer drug. Mar 5, 2019 184
Pfizer Receives Positive CHMP Opinion for Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer. Mar 4, 2019 444
Pfizer receives positive opinion for LORVIQUA from CHMP. Mar 1, 2019 127
National lung cancer screening programme could save Kiwi lives. Mar 1, 2019 961
Delivery Of Medicinal Products For The Needs Of Kot - Ruse Eood In 2 Lots. Feb 20, 2019 152
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. De Marchi, Federico; Haley, Lisa; Fryer, Henderson; Ibrahim, Junaid; Beierl, Katie; Zheng, Gang; Goc Report Feb 1, 2019 6681
ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib. Sagawa, Ray; Ohba, Takehiko; Ito, Eisaku; Isogai, Susumu Jan 1, 2018 1048
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Sui, Hongshu; Ma, Ningxia; Wang, Ying; Li, Hui; Liu, Xiaoming; Su, Yanping; Yang, Jiali Clinical report Jan 1, 2018 12468

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters